Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...

Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). Top-line data of the phase ...

On Monday, AT&T Inc T reported better-than-expected fourth-quarter results. The company posted operating revenues of $32.30 ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.